Figure 8.

Effects of Cyr 61 and FGF2 expressed via mono- and bicistronic vectors on tumor growth. (a) B16F0 cells (250,000 cells) were transplanted subcutaneously in the right flank in C57Bl/6 mice divided into four groups (n = 6): pC-RiL, pC-FGF, pC-Cyr, and pC-FGFiCyr (electrotransferred 7 days before B16F0 injections). Tumor growth was monitored three times a week 7 days after B16F0 cell implantation. Each point is the mean ± SEM of six mice per group. (**P < 0.01 versus control group). (b) Comparison of the average of subcutaneous tumors by weighing explanted tumors from mice in each group when the tumor burden in treated pC-Cyr mice required euthanasia. Data are the mean weights ± SEM from six mice per group. Experiments were performed in duplicate. (c) Quantification of capillary density in the nonischemic tibialis anterior muscles (left leg) of treated (pC-FGFiCyr, pC-Cyr, pC-FGF, or pC-FGFiL) or untreated (pC-RiL) mice using anti-CD 31 antibody and reported by µm². Data are expressed as the mean ± SEM (n = 3).